Third Optimizing Anti-Platelet Therapy in Diabetes MellitUS (OPTIMUS-3)

Exclusion Criteria

• •Thienopyridine therapy within 30 days or have a defined need for thienopyridine treatment.
• •Coronary Artery Bypass Graft (CABG) or Percutaneous Coronary Intervention (PCI) with no stent placed within 30 days.
• •Planned coronary revascularization
• •Hemoglobin A1c (HbA1c) \> or equal to 10 mg/dL within the last 3 months.
• •Received fibrolytic therapy \<24 hours prior to randomization.
• •Received non-fibrin-specific fibrinolytic therapy \<48 hours prior to randomization.
• •At risk of bleeding.
• •History of ischemic stroke, transient ischemic attack (TIA), intercranial neoplasm, arteriovenous malformation, or aneurysm.
• •Body weight \<60 kilograms (kg).
• •International Normalized Ratio (INR) \>1.5, platelet count \<100,000/mm3, or anemia (hemoglobin \<10 gm/dL) within 1 week of study entry.
• •Are receiving or will receive oral anticoagulation or antiplatelet treatment therapy.
• •Are being treated with daily non-steroidal anti-inflammatory drugs (NSAIDS).
• •Are pregnant, breast-feeding or plan to become pregnant.